Therefore, the aim of this analysis was to comprehensively assess the pre-clinical efficacy of DPP-IV inhibitors in Chinese T2DM patients and to evaluate whether the response to treatment varies with different types of DPP-IV inhibitors in such patients.3 Here, ST6GALNAC4 is linked to type 2 diabetes mellitus.